Showing 1571-1580 of 20416 results for "".
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
https://reachmd.com/programs/project-oncology/hepatocellular-carcinoma-examining-its-prevalence-and-prognostic-biomarkers/24479/Join us as we explore the prevalence of hepatocellular carcinoma along with potential prognostic biomarkers that are currently being investigated.Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
https://reachmd.com/programs/project-oncology/ctdna-muscle-invasive-bladder-cancer-niagara-data/36310/Could emerging biomarkers redefine how we assess response and recurrence risk in muscle-invasive bladder cancer? To find out, Dr. Charles Turck speaks with Dr. Petros Grivas about the key findings from the phase 3 NIAGARA trial. Together, they explore how perioperative durvalumab impacts circulatingThe Future of ITP Care: Exploring New Treatments
https://reachmd.com/programs/project-oncology/the-future-of-itp-care-exploring-new-treatments/26404/Learn about how new immune thrombocytopenia treatment options, including BTK inhibitors and immune therapies.Mechanisms of Action for IL-17 Inhibition in Treating Psoriasis and Hidradenitis Suppurativa
https://reachmd.com/programs/practical-dermatology-il-17-journal-club/mechanisms-of-action-for-il-17-inhibition-in-treating-psoriasis-and-hidradenitis-suppurativa/48808/Practical Dermatology Editorial Board member Jason E. Hawkes, MD, MS, FAAD, joins Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss articles from the Journal of Clinical Medicine and Clinics in Dermatology on how IL-17 inhibition is effective in treating psoriasis and hidradenitis suppurativa,Supplements and Cannabis in Breast Cancer Care: An Integrative Medicine Approach
https://reachmd.com/programs/project-oncology/supplements-and-cannabis-in-breast-cancer-care-an-integrative-medicine-approach/26409/Here’s how we can use an integrative medicine approach to balance evidence-based guidance on supplements and cannabis with patients’ goals.Diagnosing IgA Nephropathy: The Role of Immunofluorescence and Immunohistochemistry
https://reachmd.com/programs/frontlines-iga-nephropathy/diagnosing-iga-nephropathy-the-role-of-immunofluorescence-and-immunohistochemistry/26943/How is IgA nephropathy diagnosed and differentiated from similar diseases? Tune in to find out.The Future of IgA Nephropathy: Why Biomarkers Matter
https://reachmd.com/programs/frontlines-iga-nephropathy/the-future-of-iga-nephropathy-why-biomarkers-matter/26942/Dive into the importance of biomarkers in the intensifying pursuit of newer, more effective treatments for IgA nephropathy.ISDPA: Dr. Bhatia on JAK Inhibitors
https://reachmd.com/conferences/isdpa-midwest-derm-2024/isdpa-dr-bhatia-jak-inhibitors/27064/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, talks about his presentation on JAK inhibitors at the Illinois Society of Dermatology Physician Assistants (ISDPA) Midwest Dermatology Conference 2024."A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
https://reachmd.com/programs/the-convergence/ultrasound-clement-papadacci-inserm/39926/4D ultrasound and ultrasound localization microscopy (ULM) are reshaping non-invasive imaging, allowing clinicians to visualize entire organs—down to vessels smaller than a human hair—in dynamic, real-time detail. Dr. Clément Papadacci joins Dr. Brian McDonough to share how his groundbreaking probeManaging Immune-Related Adverse Events in Metastatic NSCLC
https://reachmd.com/programs/project-oncology/managing-iraes-metastatic-nsclc/49119/Immunotherapy-based combination regimens continue to transform the treatment landscape for metastatic non-small cell lung cancer (NSCLC). However, long-term safety findings from trials like KEYNOTE-189, CheckMate 9LA, and IMpower150 show that grade 3 or higher immune-related adverse events can occur